CER Daily Newsfeed

The Comparative Effectiveness Research Daily Newsfeed®, known for short as the CER Daily Newsfeed®, offers the latest news, research and related information on comparative effectiveness research, real-world data and evidence, value assessment and other important health care topics. 

News from Wednesday, January 12, 2022

Articles

Addressing Access Burdens

(1/11, Lisa Henderson, PharmExec) reports “...NPC conducts research and publishes peer-reviewed studies as well as white papers on topics such as patient-centered formulary and benefit design,4 and many other areas that concern pharma and the need for innovation and good evidence in science. Their research in the employee/patient area centers squarely on the effect of the choices employers are making, which can—intentionally or unintentionally—negatively impact their own employees. And while the discussions traditionally occurred in the form of healthcare coalitions, where pharma and health plans have had many helpful employer discussions, [NPC president John M. O’Brien] notes the situation is not getting better and manufacturers are now reaching out directly to employers themselves.” Full

 

PCORI's First Rapid Review: Video-Teleconferencing for Disease Prevention, Diagnosis, and Treatment

(1/12, The PCORI Blog) comments “...PCORI’s first Rapid Review summarized evidence of the benefits and harms of video-teleconferencing virtual visits for disease prevention, diagnosis, and treatment when used to augment or replace for usual care. Despite the widespread and accelerated uptake of telehealth in recent years, and especially during the COVID-19 pandemic, the relative benefits and harms of VTC compared to usual in-person care had not been thoroughly reviewed in the past five years.” Full

 

Europe Searches for Better Collaboration Across Regulators

(1/11, PharmExec) reports “...The disconnect between drug registration and pricing is notorious in Europe. Separate systems govern the two processes—with the European Medicines Agency adjudicating on the terms of the marketing authorization, and national or regional health technology assessment and pricing bodies deciding on reimbursement. Inevitably, this leads to duplications—and still more problematic, to inconsistencies—in demands for evidence. As KCE puts it, ‘the regulatory and payer processes frequently fail to generate the comparative evidence required for informed decision making.’ After review of the situation in Europe, the study concludes that action must be taken to bring the two processes more closely together.” Full

Press Releases

UNC Researchers Awarded $4.3M from PCORI to Study Strategies to Improve Health Outcomes for Youth with Intellectual and Developmental Disabilities and Their Parents

(1/11, UNC School of Medicine Press Release) “Kathleen C Thomas, PhD, MPH of the UNC Eshelman School of Pharmacy will lead a comparative effectiveness research study to improve health outcomes for youth with intellectual and developmental disability (IDD) and their parents through two parent peer group interventions, one parent-directed and one adding advocacy skills training.” Full

Journals

Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System

George Ioannou, et al.

January 7, 2022, The Lancet

The Lancet

Reports

Evidence Gaps for Drugs and Medical Devices at Market Entry in Europe and Potential Solutions

2021

KCE